OPNT - Opiant opioid overdose candidate namalfene demonstrates non-inferiority to naloxone

Nasal namalfene, a drug under development from Opiant Pharmaceuticals (NASDAQ:OPNT) for opioid overdose, met its primary endpoint of non-inferiority to nasal naltrexone in a pharmacodynamic study. Topline results showed that namalfene produced a greater reversal of respiratory depression -- about twice that produced by naloxone -- at five minutes. Nasal nalmefene, also known as OPNT003, was granted Fast Track Designation in November 2021. Opiant (OPNT) expects to complete an NDA filing in the second half of the year. Seeking Alpha's Quant Rating views Opiant (OPNT) as a buy.

For further details see:

Opiant opioid overdose candidate namalfene demonstrates non-inferiority to naloxone